What is known and the objective: Low‐grade evidence supports the use of newer biologics for otherwise refractory juvenile idiopathic arthritis (JIA)‐associated uveitis, such as tocilizumab. This report details the cases of two adolescents whose severe JIA‐ associated uveitis was unresponsive to the first‐line therapeutic approach. Tocilizumab therapy led to the remission of uveitis after a mean time of 3 weeks, and methotrexate was safely discontinued 1.5 years later. What is new and conclusion: To our knowledge, these are the first reports of suc‐ cessful methotrexate withdrawal during tocilizumab treatment of JIA‐associated uveitis. The administration of tocilizumab without methotrexate could be considered in patients with JIA‐associated uveitis unresponsive to conventional therapy.
Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: a report of two cases, Valeria Dipasquale, Marco Atteritano, Irene Castagna, Jlenia Fresta, Giovanni Conti
Valeria Dipasquale;Marco Atteritano;Irene Castagna;FRESTA, JLENIA;
2019-01-01
Abstract
What is known and the objective: Low‐grade evidence supports the use of newer biologics for otherwise refractory juvenile idiopathic arthritis (JIA)‐associated uveitis, such as tocilizumab. This report details the cases of two adolescents whose severe JIA‐ associated uveitis was unresponsive to the first‐line therapeutic approach. Tocilizumab therapy led to the remission of uveitis after a mean time of 3 weeks, and methotrexate was safely discontinued 1.5 years later. What is new and conclusion: To our knowledge, these are the first reports of suc‐ cessful methotrexate withdrawal during tocilizumab treatment of JIA‐associated uveitis. The administration of tocilizumab without methotrexate could be considered in patients with JIA‐associated uveitis unresponsive to conventional therapy.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
